[A18-53] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
|2018-12-03||Extract of dossier assessment||152 kB|
|2018-12-03||Dossier assessment (German version)||663 kB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Extract of dossier assessment
Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.